Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistDynamic Health Group dba SARMS AMERICA was cited for marketing unapproved new drugs, specifically selective androgen receptor modulators (SARMs) including Ostarine MK-2866, MK-677 Ibutamoren, Cardarine GW501516, and LGD-4033 Ligandrol, in violation of sections 301(d) and 505(a) of the FD&C Act. Despite labeling claims that products were "for research use only," the FDA determined the products were intended for human use based on evidence from the company's website and product labeling indicating intended effects on body structure or function. The FDA noted serious safety concerns associated with SARMs, including life-threatening liver toxicity and increased risk of heart attack and stroke in users.